TrialThe Lancet. Oncology2020

Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.

Mrinal Gounder et al.PubMed ↗Publisher ↗

No numbers read from the abstract.